ALK and non-small cell lung carcinoma: KEYTRUDA or OPDIVO, a human PD-1 blocking antibody, is recommended as first-line treatment for metastatic non-squamous NSCLC with no EGFR or ALK aberrations in combination with pemetrexed and platinum chemotherapy.